



US010335462B2

**(12) United States Patent  
Jensen****(10) Patent No.: US 10,335,462 B2**  
**(45) Date of Patent: \*Jul. 2, 2019****(54) USE OF LONG-ACTING GLP-1 PEPTIDES****(71) Applicant: Novo Nordisk A/S, Bagsvaerd (DK)****(72) Inventor: Christine Bjoern Jensen,**  
Charlottenlund (DK)**(73) Assignee: Novo Nordisk A/S, Bagsvaerd (DK)****(\*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

**(21) Appl. No.: 15/656,042****(22) Filed: Jul. 21, 2017****(65) Prior Publication Data**

US 2018/0085435 A1 Mar. 29, 2018

**Related U.S. Application Data****(63)** Continuation of application No. 14/409,493, filed as application No. PCT/EP2013/063004 on Jun. 21, 2013, now Pat. No. 9,764,003.**(60)** Provisional application No. 61/708,162, filed on Oct. 1, 2012, provisional application No. 61/694,837, filed on Aug. 30, 2012.**(30) Foreign Application Priority Data**Jul. 1, 2012 (EP) ..... 12174535  
Oct. 1, 2012 (EP) ..... 12186781**(51) Int. Cl.****A61K 38/26** (2006.01)  
**A61P 5/50** (2006.01)  
**A61P 3/04** (2006.01)  
**A61P 3/10** (2006.01)**(52) U.S. Cl.**CPC ..... **A61K 38/26** (2013.01)**(58) Field of Classification Search**

None

See application file for complete search history.

**(56) References Cited****U.S. PATENT DOCUMENTS**8,129,343 B2 3/2012 Lau et al.  
8,536,122 B2 9/2013 Lau et al.  
2010/0047762 A1 2/2010 Button et al.  
2010/0292133 A1 11/2010 Spetzler et al.  
2011/0301080 A1 12/2011 Bush et al.**FOREIGN PATENT DOCUMENTS**CN 102229668 A 11/2011  
RU 2409349 C2 1/2011RU 2413530 C2 3/2011  
WO 2006/097537 A2 9/2006  
WO 2010/092163 A2 8/2010  
WO 2011/080103 A1 7/2011  
WO 2011/138421 A1 11/2011  
WO 12016419 A1 2/2012  
WO 2012/080471 A1 6/2012  
WO 2012/107476 A1 8/2012  
WO 12130136 A1 10/2012  
WO 12136790 A1 10/2012  
WO 2012/177929 A2 12/2012**OTHER PUBLICATIONS**

Madsbad S et al. An Overview of once-weekly glucagon-like peptide-1 receptor agonists available efficacy and safety data and perspectives for the future, Diabetes, Obesity and Metabolism Year 2011, vol. 13, No. 5, pp. 394-407.

Buse B. J. et al., Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study, Lancet, 2013, vol. 381, pp. 117-124.

Kim et al. "Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exentide on Glucose Control and Body Weight in Subjects with Type 2 Diabetes." Diabetes care (2007) vol. 30 pp. 1487-1493.

Bydureon NDA 022200/S-008 Package Information pp. 1-179 (Feb. 2014).

Clinical Trial NCT00696657 entitled "A Randomized Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide." pp. 1-5 Mar. 2015. Accessed Sep. 24, 2015 at [clinicaltrials.gov/archive/NCT00696657/2011\\_03\\_25](http://clinicaltrials.gov/archive/NCT00696657/2011_03_25).

Lau et al. "Discovery of the Once-WEEKly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." J. Med. Chem. (2015) vol. 58 pp. 7370-7380.

Eperzan Assessment Report. Euro. Med. Agency. pp. 1-124 (2014) accessed Sep. 24, 2015 at URL [ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Public\\_assessment\\_report/human/002735/WC500165119.pdf](http://ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002735/WC500165119.pdf).Trulicity Assessment Report. Euro. Med. Agency. pp. 1-172 (2014) accessed Sep. 24, 2015 at URL [ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Public\\_assessment\\_report/human/002825/WC500179473.pdf](http://ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002825/WC500179473.pdf).

Mizuta et al. "The Role for GLP-1 in Regulation of Body Weight." Progress in Medicine 2008 vol. 28 No. 8 pp. 1909-1912.

CDC, "National Health and Nutrition Examination Survey: Healthy Weight, Overweight and Obesity among U.S. adults" 03-0260 pp. 1-2 (Jul. 2003), accessed May 10, 2016 at URL [cdc.gov/nchs/data/nhanes/databriefs/adultweight.pdf](http://cdc.gov/nchs/data/nhanes/databriefs/adultweight.pdf).*Primary Examiner* — Julie Ha*Assistant Examiner* — Kristina M Hellman**(74) Attorney, Agent, or Firm** — Leon Y. Lum**(57) ABSTRACT**

The invention relates to use of long-acting GLP-1 peptides in certain dosage regimes for the treatment of type 2 diabetes, obesity, etc.

**10 Claims, 6 Drawing Sheets****Specification includes a Sequence Listing.**